Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
HeartWare International shares are up today on the medical device company’s 1st release of data since its HVAD implantable heart pump went on the U.S. market.
HeartWare’s HVAD left ventricular assist device won pre-market approval from the FDA in November 2012 as a bridge to heart transplantation. Last week at the International Society for Heart & Lung Transplantation’s annual conference in San Diego, HeartWare for the 1st time released data from its post-approval study of commercial HVAD patients. Read more
Boston Scientific kicked off a new registry evaluating deep brain stimulation in treatment of Parkinson’s disease.
The medtech titan announced this week that it enrolled the 1st of up to 300 patients slated for participation in the registry. Researchers will follow patients implanted with Boston Scientific’s Vercise DBS system, an implantable neurostimulator that selectively stimulates targeted areas of the brain associated with movement disorders. Read more
Edwards Lifesciences notched a major win against rival Medtronic when a court ordered a preliminary injunction limiting Medtronic from selling its CoreValve transcatheter aortic valve implantation system in the U.S.
Medtronic vowed to take advantage of its 7-day window to immediately appeal the decision. Read more